Official UK procurement notice
Generic and Biosimilar Cancer Medicines
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority") (NHS & healthcare)
What is being bought41 lots · detail below
Published requirement descriptionThis Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland.
The Goods were separated into forty-one (41) categories, each of which is identified as a “Lot”.
Full details of each awarded Lot is contained in section II.2 of this Notice.
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 5 bids on the busiest of 25 lots · 29 suppliers appointed
Lots and requirements (41)Procurement structure
25 of 41 loaded on this pageShowing the first 25 of 41 published lots; the full list is in the JSON and Markdown mirrors of this notice. 41 lots · all with a published value · same evaluation weights on every lot.
Lot #1Bendamustine Powder For Solution For InfusionAwardedRenewalPublished value£94,841
Supply of Bendamustine Powder For Solution For Infusion to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #2Capecitabine TabletsAwardedRenewalPublished value£910,974
Supply of Capecitabine Tablets to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #3Carboplatin InjectionAwardedRenewalPublished value£596,546
Supply of Carboplatin Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #4Cisplatin InjectionAwardedRenewalPublished value£186,020
Supply of Cisplatin Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #5Cyclophosphamide Injection, Powder For ReconstitutionAwardedRenewalPublished value£267,442
Supply of Cyclophosphamide Injection, Powder For Reconstitution to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #6Cytarabine InjectionsAwardedRenewalPublished value£104,724
Supply of Cytarabine Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #7Dacarbazine InjectionsAwardedRenewalPublished value£592,972
Supply of Dacarbazine Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #8Disodium Folinate InjectionAwardedRenewalPublished value£442,064
Supply of Disodium Folinate Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #9Docetaxel Concentrate For Solution For InfusionAwardedRenewalPublished value£333,456
Supply of Docetaxel Concentrate For Solution For Infusion to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #10Doxorubicin Hydrochloride InjectionsAwardedRenewalPublished value£60,002
Supply of Doxorubicin Hydrochloride Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #11Fluorouracil 25MG/ML InjectionRenewalPublished value£44,750
Supply of Fluorouracil 25MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
Lot #12Fluorouracil 50MG/ML InjectionAwardedRenewalPublished value£236,261
Supply of Fluorouracil 50MG/ML Injections to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #13Gemcitabine 38MG/ML Concentrate For Solution For Infusion VialsAwardedRenewalPublished value£108,791
Supply of Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #14Gemcitabine 100MG/ML Concentrate For Solution For Infusion VialsAwardedRenewalPublished value£18,031
Supply of Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #15Gemcitabine Powder For Solution For Infusion VialsRenewalPublished value£125,603
Supply of Gemcitabine Powder For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
Lot #16Idarubicin Hydrochlioride Injection Powder For ReconstitutionRenewalPublished value£28,000
Supply of Idarubicin Hydrochlioride Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
Lot #17Ifosfamide Injection Powder For ReconstitutionAwardedRenewalPublished value£2,721,676
Supply of Ifosfamide Injection Powder For Reconstitution to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #18Irinotecan Hydrochloride InjectionAwardedRenewalPublished value£248,266
Supply of Irinotecan Hydrochloride Injection to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #19Lanreotide Injection Prefilled SyringesAwardedRenewalPublished value£4,686,468
Supply of Lanreotide Injection Prefilled Syringes to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #20Methotrexate Without Preservatives InjectionAwardedRenewalPublished value£304,589
Supply of Methotrexate Without Preservatives Injection to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #21Methotrexate Oral SolutionAwardedRenewalPublished value£56,000
Supply of Methotrexate Oral Solution to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #22Mitomycin Injection Powder For ReconstitutionRenewalPublished value£495,141
Supply of Mitomycin Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
Lot #23Oxaliplatin Vial SolutionAwardedRenewalPublished value£209,041
Supply of Oxaliplatin Vial Solution to NHS Scotland. The Authority has awarded presentations within this lot to a single supplier.
Lot #24Paclitaxel Concentrate For Intravenous InfusionAwardedRenewalPublished value£406,689
Supply of Paclitaxel Concentrate For Intravenous Infusion to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
Lot #25Temozolomide CapsulesAwardedRenewalPublished value£145,833
Supply of Temozolomide Capsules to NHS Scotland. The Authority has awarded all presentations within this lot to a single supplier.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (2)
- Logistics: 5%
- price: 95%
Published award criteria (2)
- Logistics: 5
- Price: 95
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.
Minimum: a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Tec…
- Price carries 95 of 100 points: a 10% discount moves about 9.5 points. This one is won on the number: sharpen the price before polishing the prose.
- “Generic and Biosimilar Cancer Medicines” is a framework: the contest is a place on its panel, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 16 Sept 2022, 08:41 BST
- Last source update
- 21 Apr 2023, 08:53 BST
- Award evaluation window
- 17 Oct 2022 – …
- Authority reference
NP39722- FTS notice number
2023/S 000-011419- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0368eeFind a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value referred to in Section II.I.5 and within each Lot covers the twenty-four (24) months contract duration and the full twenty-four (24) months extension options. The Goods within this procurement were separated and advertised as forty-one (41) categories, each of which was identified as a “Lot” Out of the 41 lots, 33 Lots have been awarded. For details of lots not awarded, or details of individual lines awarded within a lot contact the named person at head of notice (SC Ref:723470)
How it was run
Official notice- Appointment period ends
- 17 Oct 2022, 12:00 BST
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bid validity
- 90 days from the deadline
- Bids opened
- 17 Oct 2022, 12:00 BST
Timeline
17 Oct 2022 → 21 Apr 2023 · 3 dates- Admission / appointment period endsperiod end, not a bid countdown17 Oct 2022, 12:00 BST
- Bids opened17 Oct 2022, 12:00 BST
- Notice published21 Apr 2023, 08:53 BST
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete21 Apr 2023, 08:53 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast33 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
Lot 1 Bendamustine Powder For Solution For Infusion
- Signed
- 23 Dec 2022
- Value
- £94,841
- Status
- active
Lot 10 Doxorubicin Hydrochloride Injections
- Signed
- 23 Dec 2022
- Value
- £64,942
- Status
- active
Lot 12 Fluorouracil 50MG/ML Injection
- Signed
- 23 Dec 2022
- Value
- £254,428
- Status
- active
Lot 13 Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials
- Signed
- 23 Dec 2022
- Value
- £101,239
- Status
- active
Lot 14 Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials
- Signed
- 23 Dec 2022
- Value
- £17,172
- Status
- active
Lot 18 Irinotecan Hydrochloride Injection
- Signed
- 23 Dec 2022
- Value
- £226,125
- Status
- active
Lot 19 Lanreotide Injection Prefilled Syringes
- Signed
- 23 Dec 2022
- Value
- £2,785,640
- Status
- active
Lot 20 Methotrexate Without Preservatives Injection
- Signed
- 23 Dec 2022
- Value
- £360,972
- Status
- active
Lot 21 Methotrexate Oral Solution
- Signed
- 23 Dec 2022
- Value
- £55,538
- Status
- active
Lot 23 Oxaliplatin Vial Solution
- Signed
- 23 Dec 2022
- Value
- £193,024
- Status
- active
Lot 24 Paclitaxel Concentrate For Intravenous Infusion
- Signed
- 23 Dec 2022
- Value
- £346,754
- Status
- active
Lot 2 Capecitabine Tablets
- Signed
- 23 Dec 2022
- Value
- £748,926
- Status
- active
Lot 25 Temozolomide Capsules
- Signed
- 23 Dec 2022
- Value
- £117,608
- Status
- active
Lot 26 Vincristine Without Preservatives Injection
- Signed
- 23 Dec 2022
- Value
- £132,132
- Status
- active
Lot 27 Vinorelbine Injection
- Signed
- 23 Dec 2022
- Value
- £54,400
- Status
- active
Lot 28 Aprepitant Capsules
- Signed
- 23 Dec 2022
- Value
- £116,863
- Status
- active
Lot 31 Octreotide Injection
- Signed
- 23 Dec 2022
- Value
- £135,446
- Status
- active
Lot 32 Filgrastim Pre-Filled Syringe
- Signed
- 23 Dec 2022
- Value
- £1,670,068
- Status
- active
Lot 33 Pemetrexed Powder For Solution For Infusion Vials
- Signed
- 23 Dec 2022
- Value
- £161,249
- Status
- active
Lot 34 Pemetrexed (25Mg/Ml) Solution For Infusion Vials
- Signed
- 23 Dec 2022
- Value
- £232,447
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Bendamustine Powder For Solution For Infusion | 4bids · 4 electronic · 4 from abroad | 0 | — | — |
| 2 · Capecitabine Tablets | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| 3 · Carboplatin Injection | 4bids · 4 electronic · 4 from abroad | 0 | — | — |
| 4 · Cisplatin Injection | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| 5 · Cyclophosphamide Injection, Powder For Reconstitution | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
| 6 · Cytarabine Injections | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 7 · Dacarbazine Injections | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 8 · Disodium Folinate Injection | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 9 · Docetaxel Concentrate For Solution For Infusion | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| 10 · Doxorubicin Hydrochloride Injections | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| 12 · Fluorouracil 50MG/ML Injection | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
| 13 · Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| 14 · Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 17 · Ifosfamide Injection Powder For Reconstitution | 4bids · 4 electronic · 4 from abroad | 0 | — | — |
| 18 · Irinotecan Hydrochloride Injection | 5bids · 5 electronic · 5 from abroad | 0 | — | — |
| 19 · Lanreotide Injection Prefilled Syringes | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 20 · Methotrexate Without Preservatives Injection | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
| 21 · Methotrexate Oral Solution | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 23 · Oxaliplatin Vial Solution | 5bids · 5 electronic · 5 from abroad | 0 | — | — |
| 24 · Paclitaxel Concentrate For Intravenous Infusion | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
| 25 · Temozolomide Capsules | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
| Lot 26 | 2bids · 2 electronic | 0 | — | — |
| Lot 27 | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| Lot 28 | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| Lot 31 | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Edinburgh Sheriff CourtReview body
Framework contractors & participating bidders
29 commercial parties on the notice- Accord-UK LtdFramework contractor
- Aspen Pharmacare UK LimitedFramework contractor
- Baxter Healthcare LtdFramework contractor
- Bayer PlcFramework contractor
- Celltrion Healthcare United Kingdom LimitedFramework contractor
- Chugai Pharma UK LtdFramework contractor
- Consilient Health LtdFramework contractor
- Dr Reddy's Laboratories (UK) LtdFramework contractor
- Flexipharm Austrading LimitedFramework contractor
- Fresenius Kabi LtdFramework contractor
Show 19 more suppliers
- Glenmark Pharmaceuticals Europe LtdFramework contractor
- Intrapharm Laboratories LtdFramework contractor
- Kent Pharmaceuticals LtdFramework contractor
- Martindale PharmaFramework contractor
- Mercury Pharma GroupFramework contractor
- Morningside Pharmaceuticals LimitedFramework contractor
- Neon HealthcareFramework contractor
- Organon Pharmaceutical UK LtdFramework contractor
- Pfizer LtdFramework contractor
- Ranbaxy (UK) LtdFramework contractor
- Roche Products LtdFramework contractor
- Rosemont Pharmaceuticals LtdFramework contractor
- Sandoz LtdFramework contractor
- Selective Supplies LtdFramework contractor
- Teva UK LimitedFramework contractor
- Thornton & RossFramework contractor
- Viatris UK Healthcare LtdFramework contractor
- Zentiva Pharma UK LtdFramework contractor
- medac Pharma LLPFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.